|
Myelodysplastic Syndrome – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 229 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Myelodysplastic Syndrome - Pipeline Review, H1 2012', provides an overview of the Myelodysplastic Syndrome therapeutic pipeline. This report provides informatio.....
Introduction Global Markets Direct’s, 'Myelodysplastic Syndrome - Pipeline Review, H1 2012', provides an overview of the Myelodysplastic Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplastic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome. 'Myelodysplastic Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Myelodysplastic Syndrome. - A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myelodysplastic Syndrome pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Myelodysplastic Syndrome therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Myelodysplastic Syndrome Overview 11 Therapeutics Development 12 An Overview of Pipeline Products for Myelodysplastic Syndrome 12 Myelodysplastic Syndrome Therapeutics under Development by Companies 14 Myelodysplastic Syndrome Therapeutics under Investigation by Universities/Institutes 18 Late Stage Products 28 Comparative Analysis 28 Mid Clinical Stage Products 29 Comparative Analysis 29 Early Clinical Stage Products 30 Comparative Analysis 30 Pre-Clinical Stage Products 31 Comparative Analysis 31 Myelodysplastic Syndrome Therapeutics – Products under Development by Companies 32 Myelodysplastic Syndrome Therapeutics – Products under Investigation by Universities/Institutes 36 Companies Involved in Myelodysplastic Syndrome Therapeutics Development 67 Genzyme Corporation 67 Johnson & Johnson 68 Kyowa Hakko Kirin Co., Ltd. 69 Abbott Laboratories 70 Amgen Inc. 71 Sanofi-Aventis 72 medac GmbH 73 Merck & Co., Inc. 74 Dainippon Sumitomo Pharma Co., Ltd. 75 Gamida Cell Ltd. 76 Bio-Path Holdings, Inc. 77 Aldagen, Inc. 78 Millennium Pharmaceuticals, Inc. 79 Novartis AG 80 BioMarin Pharmaceutical Inc. 81 Cephalon, Inc. 82 Nippon Shinyaku Co., Ltd. 83 Sunesis Pharmaceuticals, Inc. 84 SuperGen, Inc. 85 Cyclacel Pharmaceuticals Inc. 86 Celgene Corporation 87 Incyte Corporation 88 Access Pharmaceuticals, Inc. 89 4SC AG 90 Lorus Therapeutics Inc 91 MethylGene Inc 92 OXiGENE, Inc. 93 Telik, Inc. 94 TopoTarget A/S 95 Array BioPharma Inc. 96 Threshold Pharmaceuticals, Inc. 97 Synta Pharmaceuticals Corp. 98 BioAlliance Pharma SA 99 Clavis Pharma ASA 100 Cellerant Therapeutics, Inc. 101 Chroma Therapeutics Ltd. 102 BioMAS Ltd. 103 S*BIO Pte Ltd 104 Stemline Therapeutics, Inc. 105 Onconova Therapeutics, Inc 106 Syndax Pharmaceuticals, Inc. 107 Concert Pharmaceuticals, Inc. 108 KaloBios Pharmaceuticals, Inc. 109 Aprea AB. 110 Targa Therapeutics Corp. 111 Myelodysplastic Syndrome – Therapeutics Assessment 112 Assessment by Monotherapy Products 112 Assessment by Combination Products 113 Assessment by Route of Administration 114 Assessment by Molecule Type 116 Drug Profiles 119 StemEx - Drug Profile 119 Vosaroxin - Drug Profile 121 Estybon - Drug Profile 123 NS-17 - Drug Profile 125 Revlimid + Procrit - Drug Profile 126 Vosaroxin + Cytarabine - Drug Profile 127 Prograf + Methotrexate - Drug Profile 129 Vidaza - Drug Profile 130 Busulfan + Cyclophosphamide - Drug Profile 131 Fludarabine Phosphate + Melphalan - Drug Profile 132 Cyclophosphamide + Etoposide + Total Body Irradiation - Drug Profile 133 Carboplatin + Thiotepa + Cyclophosphamide - Drug Profile 134 Amsacrine + Asparaginase + Cytarabine + Daunorubicin + Etoposide + Methotrexate + Mitoxantrone + Hydrocortisone - Drug Profile 135 Thymoglobulin - Drug Profile 138 Campath - Drug Profile 139 Fludarabine Phosphate + Anti-Thymocyte Globulin - Drug Profile 140 Cyclosporine + Anti-thymocyte globulin - Drug Profile 141 Vidaza - Drug Profile 142 Fludarabine Phosphate - Drug Profile 144 Ondansetron - Drug Profile 145 Treosulfan - Drug Profile 146 Revlimid - Drug Profile 147 Busulfan + Fludarabine + Cyclophosphamide + Radiation Therapy + Transplantation - Drug Profile 149 Asparaginase + Cytarabine + Daunorubicin + Etoposide + Thioguanine - Drug Profile 150 Epoetin Alfa + Filgrastim - Drug Profile 152 Cytarabine + Etoposide + Idarubicin - Drug Profile 153 Aldesleukin + Filgrastim + Asparaginase + Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Fludarabine Phosphate + Idarubicin + Methotrexate + Therapeutic Hydrocortisone + Thioguanine + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 155 Anti-Thymocyte Globulin + Cyclosporine - Drug Profile 159 Deferasirox - Drug Profile 160 Cytarabine + Mitoxantrone Hydrochloride + Etoposide - Drug Profile 161 Idarubicin + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 163 Mitoxantrone Hydrochloride + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 165 Decitabine - Drug Profile 167 Idarubicin + Cyclophosphamide + Busulfan + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 168 Busulfan + Cyclophosphamide + Melphalan + Allogeneic Hematopoietic Cell Transplantation - Drug Profile 170 Cyclophosphamide + Cyclosporine + Methotrexate + Stem Cell Transplantation + Radiation Therapy - Drug Profile 171 Busulfan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 173 Tacrolimus + Sirolimus - Drug Profile 175 Umbilical Cord Blood Transplantation - Drug Profile 176 bone marrow transplantation + T cell-depleted bone marrow transplantation - Drug Profile 178 Alemtuzumab + Arsenic Trioxide + Azacitidine + Busulfan + Clofarabine + Cytarabine + Daunorubicin Hydrochloride + Fludarabine Phosphate + Gemtuzumab Ozogamicin + Melphalan + Tipifarnib + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 179 Bone Marrow Transplantation - Drug Profile 182 Cytarabine + Daunorubicin + Etoposide + Hydroxyurea + Idarubicin + Mitoxantrone + Thioguanine + Tretinoin + Valspodar - Drug Profile 183 5-Azacytidin - Drug Profile 186 Cyclophosphamide + Total Body Irradiation - Drug Profile 187 Cyclosporine + Methotrexate - Drug Profile 189 Fludarabine + Busulfan + Cyclophosphamide + Radiation Therapy + Allogeneic Stem Cell Transplantation - Drug Profile 191 Myelodysplastic Syndrome Therapeutics – Drug Profile Updates 193 Myelodysplastic Syndrome Therapeutics – Discontinued Products 200 Myelodysplastic Syndrome Therapeutics - Dormant Products 204 Myelodysplastic Syndrome – Product Development Milestones 216 Featured News & Press Releases 216 Appendix 225 Methodology 225 Expert Panel Validation 226 Contact Us 226 Disclaimer 226 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Myelodysplastic Syndrome, H1 2012 15 Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H1 2012 16 Number of Products under Development by Companies, H1 2012 18 Number of Products under Development by Companies, H1 2012 (Contd..1) 19 Number of Products under Development by Companies, H1 2012 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2012 22 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 23 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 24 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 26 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 27 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 28 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 29 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 30 Comparative Analysis by Late Stage Development, H1 2012 31 Comparative Analysis by Mid Clinical Stage Development, H1 2012 32 Comparative Analysis by Early Clinical Stage Development, H1 2012 33 Comparative Analysis by Pre-Clinical Stage Development, H1 2012 34 Products under Development by Companies, H1 2012 35 Products under Development by Companies, H1 2012 (Contd..1) 36 Products under Development by Companies, H1 2012 (Contd..2) 37 Products under Development by Companies, H1 2012 (Contd..3) 38 Products under Investigation by Universities/Institutes, H1 2012 39 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 40 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 41 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 42 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 43 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 44 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 45 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 46 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 47 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 48 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 49 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 50 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 51 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 52 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 53 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 54 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 55 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 56 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 57 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 58 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 59 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 60 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 61 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 62 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 63 Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 64 Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 65 Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 66 Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 67 Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 68 Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 69 Genzyme Corporation, H1 2012 70 Johnson & Johnson, H1 2012 71 Kyowa Hakko Kirin Co., Ltd., H1 2012 72 Abbott Laboratories, H1 2012 73 Amgen Inc., H1 2012 74 Sanofi-Aventis, H1 2012 75 medac GmbH, H1 2012 76 Merck & Co., Inc., H1 2012 77 Dainippon Sumitomo Pharma Co., Ltd., H1 2012 78 Gamida Cell Ltd., H1 2012 79 Bio-Path Holdings, Inc., H1 2012 80 Aldagen, Inc., H1 2012 81 Millennium Pharmaceuticals, Inc., H1 2012 82 Novartis AG, H1 2012 83 BioMarin Pharmaceutical Inc., H1 2012 84 Cephalon, Inc., H1 2012 85 Nippon Shinyaku Co., Ltd., H1 2012 86 Sunesis Pharmaceuticals, Inc., H1 2012 87 SuperGen, Inc., H1 2012 88 Cyclacel Pharmaceuticals Inc., H1 2012 89 Celgene Corporation, H1 2012 90 Incyte Corporation, H1 2012 91 Access Pharmaceuticals, Inc., H1 2012 92 4SC AG, H1 2012 93 Lorus Therapeutics Inc, H1 2012 94 MethylGene Inc, H1 2012 95 OXiGENE, Inc., H1 2012 96 Telik, Inc., H1 2012 97 TopoTarget A/S, H1 2012 98 Array BioPharma Inc., H1 2012 99 Threshold Pharmaceuticals, Inc., H1 2012 100 Synta Pharmaceuticals Corp., H1 2012 101 BioAlliance Pharma SA, H1 2012 102 Clavis Pharma ASA, H1 2012 103 Cellerant Therapeutics, Inc., H1 2012 104 Chroma Therapeutics Ltd., H1 2012 105 BioMAS Ltd., H1 2012 106 S*BIO Pte Ltd, H1 2012 107 Stemline Therapeutics, Inc., H1 2012 108 Onconova Therapeutics, Inc, H1 2012 109 Syndax Pharmaceuticals, Inc., H1 2012 110 Concert Pharmaceuticals, Inc., H1 2012 111 KaloBios Pharmaceuticals, Inc., H1 2012 112 Aprea AB., H1 2012 113 Targa Therapeutics Corp., H1 2012 114 Assessment by Monotherapy Products, H1 2012 115 Assessment by Combination Products, H1 2012 116 Assessment by Stage and Route of Administration, H1 2012 118 Assessment by Molecule Type, H1 2012 121 Myelodysplastic Syndrome Therapeutics – Drug Profile Updates 196 Myelodysplastic Syndrome Therapeutics – Discontinued Products 203 Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..1) 204 Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..2) 205 Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..3) 206 Myelodysplastic Syndrome Therapeutics – Dormant Products 207 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..1) 208 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..2) 209 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..3) 210 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..4) 211 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..5) 212 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..6) 213 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..7) 214 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..8) 215 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..9) 216 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..10) 217 Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..11) 218 List of Figures Number of Products under Development for Myelodysplastic Syndrome, H1 2012 15 Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H1 2012 16 Products under Development by Companies, H1 2012 17 Products under Investigation by Universities/Institutes, H1 2012 21 Late Stage Products, H1 2012 31 Mid Clinical Stage Products, H1 2012 32 Early Clinical Stage Products, H1 2012 33 Pre-Clinical Stage Products, H1 2012 34 Assessment by Monotherapy Products, H1 2012 115 Assessment by Combination Products, H1 2012 116 Assessment by Route of Administration, H1 2012 117 Assessment by Stage and Route of Administration, H1 2012 118 Assessment by Molecule Type, H1 2012 119 Assessment by Stage and Molecule Type, H1 2012 120 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
